Phase I/II Trial of Nano-camptothecin CRLX101 with Capecitabine and Radiotherapy as Neoadjuvant Treatment for Locally Advanced Rectal Cancer

CRLX101 is a nanoparticle-drug conjugate with a camptothecin payload. We assessed the toxicity and pathologic complete response (pCR) rate of CRLX101 with standard neoadjuvant chemoradiotherapy (CRT) in locally advanced rectal cancer. A single-arm study was conducted with a 3+3 dose escalation phase...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Nanomedicine
Päätekijät: Sanoff, Hanna K., Moon, Dominic H., Moore, Dominic T., Boles, Jeremiah, Bui, Courtney, Blackstock, William, O’Neil, Bert H., Subramaniam, Somasundaram, McRee, Autumn J., Carlson, Cheryl, Lee, Michael S., Tepper, Joel E., Wang, Andrew Z.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2019
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7881832/
https://ncbi.nlm.nih.gov/pubmed/30858085
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.nano.2019.02.021
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia